Compare Cassava Sciences Inc (FLNA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SYSCO Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while SYSCO Corporation trades at $82.46 (market cap $38.60B). The key difference: SYSCO Corporation is far larger — about 726.4× Cassava Sciences Inc's market cap, and SYSCO Corporation pays a 2.73% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SYY | |
|---|---|---|
Market Cap | $53.14M | $38.60B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $91.16 |
52-Week Low | $1.09 | $69.30 |
Enterprise Value | -$33.43M | $52.08B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SYY trades at $82.32, down 0.64% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026. Revenue growth remains steady, reaching $81.37B in 2025, while net income margin is 2.08%. The company maintains positive cash flow and announced a $0.55 dividend for July 2026.
Outlook is positive with a consensus price target of $83.67, though risks include margin pressure and debt levels. The stock offers value with a P/S of 0.47, but investors should monitor Q2 2026 earnings and industry headwinds. Institutional sentiment is bullish, with 60% buy ratings among analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
